Abstract:

Purpose: Plasmaferase has been used for the last 40 years in the treatment of immunological renal diseases. The mechanism under this approach is the cleaning of pathogenic immune mediators such as antibodies and immune complexes from circulation. This study is aimed at retrospective assessment of patients who are treated with plasmaferase in our clinic. Tools and Methods: In the last 10 years, the records of 27 patients in our clinic and therapeutic plasmaferase treatment have been evaluated. Demographic characteristics, biochemical parameters, biopsy results, plazmaferase complications and post-treatment survival were recorded. Results: The average age of patients was 39±18 (17-71) years, the average number of plasmaferase sessions was 13.9±8.8 (2-41) years. In six patients Goodpasture disease, in 5 patients ANCA (+) small vasculitis, in 5 patients thrombotic microangiopathy, in 4 patients systemic lupus erythematosis, in 3 patients acute humorous rejection, in 3 patients primary kresentic glomerulonefritis and in 1 patients multiple myelom were detected. During the treatment, one patient was exitus, 9 patients saw kidney healing, 12 patients began dialytic treatment due to kidney failure in the last period. In one of the patients diagnosed renal recovery, a nickel was detected, and in a total of 6 patients, stage 2-3 renal insufficiency continued. The result: Plasmaferase nefrology clinics should be considered as adjuvant treatment in some specific groups of patients. The last period can prevent the progression of kidney failure and cause acceleration in renal recovery.

Keywords: